十几岁的埃斯利卡巴塞过量服用:病例描述和治疗方法
Maria Kavga1, Jobst Rudolf2, Foteini Mitsa3
14th Department of Pediatrics, Medical School (MK,MF,PP), Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece.
概括
在青少年中过量服用埃斯利卡巴泽平酸盐是罕见的,但可能导致神经毒性. 治疗包括用于脏清理的利尿剂和用于激发管理的利和米达佐拉姆等药物.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 青少年医学 青少年医学
背景情况:
- 埃斯利卡巴泽酸是一种较新的抗药物,已被批准用于青少年.
- 有限的数据存在于eslicarbazepine酸盐剂量和青少年过量.
研究的目的:
- 报告一个罕见的病例,在一个健康的青少年中,有意过量服用埃斯利卡巴泽酸.
- 描述过量服用后的神经毒性的临床表现和管理.
主要方法:
- 一个青少年的病例报告有意过量服用埃斯利卡巴泽酸.
- 治疗包括支持性护理,用利尿剂过度水分,激发时用哈洛佩里多尔,控制症状时使用米达佐拉姆.
主要成果:
- 患者在故意过量服用后出现神经毒性.
- 用利尿剂,利和米达佐拉姆治疗促进了快速的药物清除,并控制了激动.
结论:
- 过量服用埃斯利卡巴泽酸可导致青少年显著的神经毒性.
- 包括利尿剂和镇静剂在内的积极管理可以有效地管理过量症状并增强排泄.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
289
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
289
Mania and Antimanic Drugs: Overview
328
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
328
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
461
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
461
Epilepsy and Seizures: Overview
296
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
296
Psychosis: Goals of Pharmacotherapy
214
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
214
Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K


